Literature DB >> 11926377

[18F]FLT; portrait of a proliferation marker.

W Mier, U Haberkorn, M Eisenhut.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11926377     DOI： 10.1007/s00259-001-0675-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  21 in total

1.  Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Jinming Yu; Xiaorong Sun; Dianbin Mu; Anqin Han
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

2.  Imaging proliferation of ¹⁸F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Xiaorong Sun; Dianbin Mu; Jinming Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-12       Impact factor: 9.236

3.  [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.

Authors:  Seung Jin Choi; Jae Seung Kim; Jeong Hoon Kim; Seung Jun Oh; Jeong Gyo Lee; Chang Jin Kim; Young Shin Ra; Jeong Seok Yeo; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-15       Impact factor: 9.236

Review 4.  Evolving role of FDG PET imaging in assessing joint disorders: a systematic review.

Authors:  Kathleen Carey; Babak Saboury; Sandip Basu; Alex Brothers; Alexis Ogdie; Tom Werner; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-14       Impact factor: 9.236

5.  Clinical relevance of imaging proliferative activity in lung nodules.

Authors:  Andreas K Buck; Martin Hetzel; Holger Schirrmeister; Gisela Halter; Peter Möller; Clemens Kratochwil; Andreas Wahl; Gerhard Glatting; Felix M Mottaghy; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-14       Impact factor: 9.236

6.  Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging.

Authors:  Yingding Xu; Edwin Chang; Hongguang Liu; Han Jiang; Sanjiv Sam Gambhir; Zhen Cheng
Journal:  J Nucl Med       Date:  2012-01-12       Impact factor: 10.057

7.  3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging.

Authors:  Yuka Yamamoto; Terence Z Wong; Timothy G Turkington; Thomas C Hawk; David A Reardon; R Edward Coleman
Journal:  Mol Imaging Biol       Date:  2006 Nov-Dec       Impact factor: 3.488

Review 8.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

9.  Assessment of cellular proliferation in tumors by PET using 18F-ISO-1.

Authors:  Farrokh Dehdashti; Richard Laforest; Feng Gao; Kooresh I Shoghi; Rebecca L Aft; Brian Nussenbaum; Friederike H Kreisel; Nancy L Bartlett; Amanda Cashen; Nina Wagner-Johnston; Nina Wagner-Johnson; Robert H Mach
Journal:  J Nucl Med       Date:  2013-01-28       Impact factor: 10.057

10.  3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.

Authors:  Eliot T McKinley; R Adam Smith; Ping Zhao; Allie Fu; Samir A Saleh; Md Imam Uddin; M Kay Washington; Robert J Coffey; H Charles Manning
Journal:  J Nucl Med       Date:  2013-01-22       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.